Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07519525 · ClinicalTrials.gov registry record · Phase 1
A Study of [14C]-LY4064809 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT07519525 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 7 participants.
The verdict
NCT07519525, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.
Interventions
- DRUG LY4064809
- DRUG [14C]-LY4064809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2026-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07519525
The ClinicalTrials.gov registry entry for NCT07519525 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY4064809 is the first listed.
NCT07519525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07519525 about?
NCT07519525 is a clinical study titled "A Study of [14C]-LY4064809 in Healthy Participants". The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including ...
What is the current status of trial NCT07519525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2026-03-27. Estimated completion is 2026-05-26.
What interventions are being tested in trial NCT07519525?
The interventions under investigation include: LY4064809 (DRUG), [14C]-LY4064809 (DRUG).
Who is sponsoring clinical trial NCT07519525?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.